InterCure 배당 및 자사주 매입
배당 기준 점검 0/6
InterCure 배당금을 지급한 기록이 없습니다.
핵심 정보
n/a
배당 수익률
-1.1%
자사주 매입 수익률
| 총 주주 수익률 | -1.1% |
| 미래 배당 수익률 | n/a |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | n/a |
최근 배당 및 자사주 매입 업데이트
업데이트 없음
Recent updates
Seeking Alpha • Jun 30
InterCure: A Cannabis Industry Leader Still Flying Under The Radar
Summary InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken. Pharmaceutical Cannabis industry is poised for significant growth in the coming years. InterCure stock should be considered poorly valued. Read the full article on Seeking AlphaSeeking Alpha • Apr 22
InterCure: Bargain Israel Cannabis Play
Summary InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limited to medical use, with expansion to medical cannabis patient access to grow the market in 2024. InterCure stock is cheap at only about 1x sales, with catalysts for growth in 2024 and beyond. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
InterCure: A Leader In Global Cannabis
Summary The global cannabis market will eventually be far bigger than North America. InterCure is a leading company in global pharmaceutical cannabis. Investors can still get in early while most attention is focused elsewhere. InterCure's Chairman is a national hero and former prime minister. Different routes to success in cannabis One of the enjoyable aspects of writing for Seeking Alpha is introducing readers to smaller companies that are taking an unusual and interesting approach to cannabis. These companies are mostly overlooked by analysts and the media, but offer something different -- and potentially profitable -- for the open-minded investor. Every new industry eventually consolidates around a few dominant companies through a process that takes many years. I discussed this in an article titled Trulieve: Why You Must Own This Future Dominant Cannabis Company. However, there is still great potential among other, smaller, companies. Their strategies for success are various, but each one has something that sets them apart. This difference opens an alternative path that may, or may not, lead to success, and makes them worthy of our attention. In this article we will discuss one such company: InterCure, Ltd (INCR). This report draws on a recent interview with InterCure CEO Alex Rabinovitch and a series of emails with Communications Officers Adam Haliva and Ori Mandelabum. Courtesy of Intercure. InterCure: The company InterCure is an Israeli company listed on NASDAQ. Its home cannabis market is 100% pharmaceutical. There has been some discussion of adult use, but due in part to the dysfunctional government in Israel it's still some ways off. Cannabis is very highly regulated. Patients must receive a prescription, and doctors must have a special license to prescribe. Legalization began after decades of research on medical cannabis (THC was first isolated in Israel in 1964), and has grown to the point that Israel, and InterCure in particular, are important players in the global industry ex North America. The global cannabis market Cannabis investors owe it to themselves to learn about the global market. This market will eventually exceed the North American market by several times. In addition, it is currently at a much earlier stage, and has a longer growth runway. Although the global market has its challenges, many of the barriers hindering North American companies are absent. There are no barriers to financial services or uplisting, and no confiscatory 280E taxes. Federal legalization is not paralyzed by special interest politics. Two cannabis legalization models There are two models for legal cannabis. Medical cannabis is the model for North America, with which we are familiar. Cannabis is legalized on a medical basis first. Companies and products are regulated but free to offer cannabis in any form. Eventually cannabis is legalized for adult use, and the two programs exist side by side. The second approach is pharmaceutical cannabis, and it is the model in the entire rest of the world, 40 countries so far and counting. Cannabis is put in the same category as other drugs and supervised by the same regulatory bodies (compare to the US, where the FDA has been mostly silent). It is highly restricted, regulated and monitored from seed to sale. It is much more demanding in terms of expertise and resources than the North American medical model. The endgame is still adult use as liberalizing attitudes and regulation reach their final state, but as it will be regulated by the countries it is expected to be highly regulated too. Companies are willing to take on the extra challenges because of the huge growth potential in a nascent industry. InterCure in Israel InterCure has been building its pharmaceutical cannabis business since 2008. and is the biggest pharma cannabis manufacturer outside of North America. In Israel cannabis can only be sold in special pharmacies, and InterCure has the only chain of cannabis dedicated pharmacies. It is number one in sales in Israel, which has the highest percentage of cannabis users of any country in the world. In a European study cited by Israeli Cannabis Magazine 27% of adult Israelis used it in the past year, and 19% in the past month. The Czech Republic was second in annual use at 11.4% and France was third at 11.3%. The annual use is around 25% in the US according to a YouGov survey, and was 16% in 2018 according to the National Institute of Drug Abuse. 1.3% of Israelis have medical cannabis monthly prescriptions. In the latest earnings call, InterCure's CEO estimates that number will eventually be as high as 5%,which would be 400% market growth. The company clearly has a strong domestic business base. InterCure international strategy InterCure has identified four other core target markets for growth: Germany, UK, Australia, and Austria. In addition, they have high demand for their branded products in other countries, including Switzerland and China. International expansion has been a successful growth strategy for companies based in Israel, with Wix (WIX), Sodastream and Teva (TEVA) being well-known examples. For ambitious companies it's almost essential in a country of only 8.8 million people. InterCure has been building its international capabilities for some years. They are currently number one in pharma cannabis sales in the world. They have six cultivation sites around the world and a supply chain reaching four continents. There are business relationships with a number of companies, including OrganiGram (OGI), Charlotte's Web (CWBHF), Tilray (TLRY), Teva, and Cookies. Cookies is the most powerful cannabis brand in the world, years ahead of anyone else. I encourage readers to look at their website to see why. Intercure Cookies branded store in Beersheva (Courtesy of Intercure.) InterCure's strategy is to replicate the pharmaceutical model they have developed successfully in Israel. Other companies, like Tilray, Canopy Growth (CGC) and Curaleaf (CURLF), are starting to operate in the international arena, but none have InterCure's expertise, experience, or record of success. By getting established early they will be well positioned when countries reach the promised land of adult use. When that happens, the company with the best infrastructure, relationships and brands will be in a powerful position to be one of the dominant companies. InterCure's unique asset InterCure has one additional powerful and unique advantage. The Chairman of the Board is Ehud Barak. To illustrate the impact, imagine that a combination of Colin Powell and Barack Obama became the Chairman of a company like Green Thumb (GTBIF). Mr. Barak is a former Lt. General in the Israeli Defense Forces and the most decorated soldier in Israel's history. He was defense minister and deputy prime minister in several governments. He has also served as Prime Minister of Israel. Mr. Barak is not a figurehead. He has a long time involvement in cannabis and helped InterCure import the first cannabis into Israel after the import ban ended in 2017. Ehud Barak and INCR team at TSX market opening from southern cultivation site. (Courtesy of Intercure.) Risks There are risks with any emerging growth industry company. In InterCure's home market, while there is continuing slow liberalization, the regulatory environment is challenging. In one recent example, when the cannabis licenses for a group of doctors were suspended, it materially harmed the company's results for the quarter. The domestic market is also highly competitive. Everyone wants to do business in a country with the highest proportion of cannabis users in the world. InterCure has demonstrated superior execution so far, to become number one there, and must continue that trend. The international market is also becoming highly competitive, Tilray, Curaleaf, Canopy, and other big firms have moved into the space. InterCure announced Q2 2022 results on August 15 Highlights: Revenue was $37 million [CAD], up 9% sequentially and 100% over Q2 2021. Gross profit was up 16% to $16 million, for a respectable gross margin of 43%. Operations cash flow was positive for the eighth consecutive quarter at $.3 million, and the cash balance is $96 million. Adjusted EBITDA was up 4% sequentially to $9 million, for a relatively low 23% margin. Net income was $6 million, or $0.13 per share.Seeking Alpha • Aug 15
InterCure reports Q2 results
InterCure press release (NASDAQ:INCR): Q2 net income of $6M, representing a 160% Y/Y growth Revenue of $37M. Adjusted EBITDA increased 90% year-over-year to $9 million, representing 23% of revenues and 4% sequential growth.Seeking Alpha • Jun 07
InterCure Is Growing In The Massive Global Cannabis Market
Most of cannabis industry growth will occur outside North America. The road to global growth starts with medical cannabis. InterCure is leveraging its expertise to take advantage of domestic and international growth.Seeking Alpha • Feb 16
IntureCure: Israel Recreation Cannabis Boom On The Way
InterCure provided strong preliminary results for Q4'21. The Israeli company has a major catalyst in the future approval of recreational cannabis in their home country. The stock is cheap trading at less than 3x '22 sales targets with major catalysts ahead.Seeking Alpha • Nov 08
InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)
Recent Nasdaq entrant InterCure is the most profitable cannabis company outside North America. Chairman Ehud Barak, Israel's former Prime Minister, and CEO Alex Rabinovitch discuss Israel's cannabis landscape, Europe's gradual progress and US legalization. Partnerships with companies like Tilray, Cookies and OrganiGram. The importance of fundamentals.Seeking Alpha • Sep 19
InterCure: Internationally Profitable Cannabis (Podcast Transcript)
InterCure is the most profitable cannabis company outside North America and recently uplisted to Nasdaq. Israel's former Prime Minister, Chairman Ehud Barak and CEO Alex Rabinovitch join the podcast to discuss Israel's cannabis landscape and what investors can expect going forward. Europe's gradual progress, building a strong brand with top international names. Upside remains.Seeking Alpha • Sep 09
InterCure: Ignored Uplisting
InterCure reported exceptional Q2'21 revenues with numbers up 400% over last year. The Israeli cannabis company recently uplisted to the Nasdaq to limited fanfare. The stock remains cheap at an EV of ~2.5x '22 sales targets, a major discount to Canadian cannabis stocks.지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 INCR 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: INCR 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| InterCure 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (INCR) | n/a |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.2% |
| 업계 평균 (Pharmaceuticals) | 2.2% |
| 분석가 예측 (INCR) (최대 3년) | n/a |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 INCR 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 INCR 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 INCR 의 지급 비율을 계산하기에는 데이터가 부족합니다.
주주 현금 배당
현금 흐름 범위: INCR 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/06 13:33 |
| 종가 | 2026/05/06 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
InterCure Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matt Bottomley | Canaccord Genuity |
| Vivien Azer | TD Cowen |